MediWound currently markets NexoBrid which is approved for eschar removal in adult and pediatric patients with deep partial thickness and/or full thickness thermal burns in several geographies ...

MediWound’s first drug, NexoBrid ®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need ...

The Trump administration is significantly expanding its powers to quickly deport illegal immigrants, one of a number of rapid-fire moves made by the administration to fulfill its promise to launch ...

YAVNE, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive ...

Google has agreed to purchase 100,000 tons of carbon dioxide removal credits from Indian startup Varaha, its first such deal with a carbon project in India and the largest involving biomass ...

While promoting his new movie Dog Man on the Friday, Jan. 31 episode Today, Davidson opened up about the incredibly painful removal process. "It’s pretty terrible, so if anybody out there is ...

MediWound's first drug, NexoBrid ®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need for ...

The deal - signed by Google and Indian supplier Varaha - is one of the biggest ever involving biochar, and is the tech giant's first foray into India's carbon dioxide removal (CDR) sector.